Adaptive Biotechnologies COO Julie Rubinstein sells $708,557 in stock
At a glance
- $ADPT today−0.32%last $27.78
- Vs industry peers+1.53 pts6-peer median −1.86% · ahead
- Since Nov 10−6.93%from the first trade after the story
- 52-week range13.8% below high$12.00 – $32.21
- Cash runway~8.9 yrs$75.6M cash ÷ $706K/mo burn · 10-Q
- In the headline$708,557Amount
Nothing reported about adaptive biotechnologies across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Julie Rubinstein’s $708,557 stock sale is a clear signal — but only if you know what to look for in the numbers.
- How the stock is trading: $ADPT -0.32% in the latest session.
- Timing: It was published overnight, so the session change shown belongs to a day that had already closed. Market holidays are not detected.
Where the stock stands
Adaptive Biotechnologies Corpor ($ADPT) edged down 0.32% to $27.78 in the latest session. Over the past month it is up 16.0%. It now sits 14% under the 52-week high of $32.21 and 132% above the year's low of $12.00. The year's high was 2.7 times its low, which makes double-digit swings fairly routine here.
What the filings say
In its latest report (10-Q, filed Nov 4, 2026), $ADPT earned $2.9M over the quarter to Sep 30, 2026 on revenue of $83.9M (+17.3% QoQ). Operations used $6.3M of cash over the nine months to Sep 30, 2026 — about $706K a month — against $75.6M in cash on Sep 30, 2026. At that pace the cash covers about 8.9 years. Its most recent filings before this story: 10-Q on Nov 4, 2026, 8-K on Nov 4, 2026, 10-Q on Aug 4, 2026. Figures are as filed with the SEC; the $ADPT page has the full statements.
How much coverage it is getting
Wook has filed 4 stories on Adaptive Biotechnologies Corpor in the last 30 days, 2 of them this week. That is well above its usual pace: over the month it has averaged about 1 a week. Going by their wording, 0 read bullish, 4 neutral and 0 bearish. This one reads neutral too, in line with most of them. Investing.com wrote 4 of the 4 (100%), so the count reflects one outlet's output more than broad attention.
The bigger picture
In healthcare, timing is everything. A single trial result or FDA decision can shift a drugmaker’s fate, while broader policy changes ripple across the sector. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
The $ADPT page has the full chart, filings, and valuation model. Compare one outlet with another to see if the story is confirmed or just repeated. Wook AI can pull live data and run the numbers on request.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 11, 2026. $ADPT has moved -6.93% ($29.85 to $27.78). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
